The Journal For Nurse Practitioners provides a succinct overview of atypical femoral fractures and bisphosphonates. These popular agents account for 14 million prescriptions annually in the United States.
Lyme disease remains endemic in many parts of North America and continues as a public health concern. This article reviews endemic and nonedemic areas, the lack of an available Lyme vaccine, immune pathways and what is known about the vector and bug.
The HLA-DRB1 haplotype is a known risk factor for RA.
Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.
Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.
Professor Fergus Shanahan, a consultant gastroenterologist and professor of medicine at University College Cork, has an issue with the label “auto-immune” disease being applied to conditions such as RA, lupus, multiple sclerosis, Crohn’s disease, asthma and type 1 diabetes.
The traditional FDA pregnancy risk categories (A, B, C, D, X) have been scrapped in favor of a new labeling mandate called the pregnancy and lactation labeling rule (PLLR). This change has been under consideration at the FDA for nearly 2 years and was brought about by the belief that the old
Using administrative claims data, Doctor Jas Singh and colleagues examined readmission rates after hip or knee replacement surgery. RA patients had a higher rate of readmission (8.5% vs 6.7%) compared to OA.
Impaired renal function is a known primary contributor to hyperuricemia and risk of gout.
The new Medicare Physician Fee Schedule will allow for reimbursement for chronic care management services (CCM).
Patients with osteoporosis had a significantly higher risk of sudden sensorineural hearing loss (SSNHL) than those without osteoporosis, according to the first and largest Asian population-based study to demonstrate a relationship between the two conditions.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
